カルペリチド注射液による血管障害の危険因子の解析

抄録

Carperitide has been used clinically for management of acute heart failure because of its pharmacological actions; that is, vasodilation that reduces both preload and afterload, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system (RASS). However, carperitide often induces infusion-related phlebitis despite infusion at the recommended concentration and dosing rate at Oita Oka Hospital. Therefore, we retrospectively investigated the incidence and risk factors for carperitide infusion-related phlebitis. During January to December 2016, a total of 166 patients who received precision continuous infusion of carperitide from the peripheral vein were enrolled in this study. Carperitide infusion-related phlebitis occurred in 63 (38.0％) of 166 patients. Univariate and multivariate analyses revealed that “the dosing period over 72 hours” was significantly associated with an increased risk of carperitide infusion-related phlebitis. The odds ratio (OR) and 95％ confidence interval (95％ CI) for the occurrence of phlebitis with respect to “the dosing period over 72 hours” were 4.53 (2.07-9.91). To minimize the risk of carperitide infusion-related phlebitis, we propose that medical professionals consider changing the infusion site every 72 hours at least.